Name: | pantoprazole |
---|---|
PubChem Compound ID: | 11181988 |
Molecular formula: | C16H15F2N3O4S |
Molecular weight: | 383.371 g/mol |
Name: | pantoprazole |
---|---|
Name (isomeric): | DB00213 |
Drug Type: | small molecule |
Synonyms: |
Pantoprazole Na; Pantoprozole; Pantoprazolum [INN-Latin]; Pantoprazol [INN-Spanish]; Pantoprazole Sodium
|
Brand: | Protonix I.V., Protonix IV, Protonix, Pantopan, Pantoloc, Pantor, Astropan, Pantozol, Protium |
Category: | Anti-Ulcer Agents, Proton-pump Inhibitors |
CAS number: | 102625-70-7 |
Indication: | Short-term (up to 16 weeks) treatment of erosive esophagitis. |
---|---|
Pharmacology: | Pantoprazole is a substituted benzimidazole indicated for the short-term treatment (up to 16 weeks) in the healing and symptomatic relief of erosive esophagitis. Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production. |
Mechanism of Action: |
Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production by forming a covalent bond to two sites of the (H+,K+ )- ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect is dose- related and leads to inhibition of both basal and stimulated gastric a...
show more » |
Absorption: | Pantoprazole is well absorbed. It undergoes little first-pass metabolism resulting in an absolute bioavailability of approximately 77%. |
Protein binding: | 98% |
Biotransformation: | Pantoprazole is extensively metabolized in the liver through the cytochrome P450 (CYP) system. The main metabolic pathway is demethylation, by CYP2C19, with subsequent sulfation; other metabolic pathways include oxidation by CYP3A4. There is no evidence that any of the pantoprazole metabolites have significant pharmacologic activity. |
Route of elimination: | After administration of a single intravenous dose of 14C-labeled pantoprazole to healthy, normal metabolizer subjects, approximately 71% of the dose was excreted in the urine with 18% excreted in the feces through biliary excretion. |
Half Life: | 1 hour |
Clearance: | 7.6-14.0 L/h |
Toxicity: | Single intravenous doses of pantoprazole at 378, 230, and 266 mg/kg (38, 46, and 177 times the recommended human dose based on body surface area) were lethal to mice, rats and dogs, respectively. The symptoms of toxicity included hypoactivity, ataxia, hunched sitting, limb-splay, lateral position, segregation, absence of ear reflex, and tremor. There is limited experience regarding cases of human overdosage, and treatment should be symptomatic and supportive. |
Affected organisms: | Humans and other mammals |
Food interaction: |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Drug interaction: |
|